The FDA has granted Breakthrough Device Designation to PathAI’s PathAssist Derm, an AI-powered tool designed to analyze digital pathology images of skin lesions and assist pathologists in diagnostic review.
Fewer than 15% of US healthcare organizations have selected a digital pathology vendor, according to a new KLAS report, which also finds higher customer satisfaction with pathology-specific companies.
The FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.'s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.
The AI companion analyzes up to five years of personal lab data within the company's patient portal to explain test results and identify health trends.
Research in bone marrow transplant patients with blood cancers and febrile neutropenia suggests the host-response test may help identify infection in high-risk populations.
